文献速递姑息放疗与转移瘤胸部肿瘤放疗

L19-白细胞介素2联合立体定向体部放疗的毒性:一项1期研究

Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-12-04

这项1期剂量递增研究评估寡转移实体瘤患者在接受根治性SBRT后1周内静脉给予免疫细胞因子L19-IL2的安全性,主要终点为不良事件。15 Mio IU剂量组未见剂量限制性毒性,22.5 Mio IU组3例均出现剂量限制性毒性但无后遗症恢复。推荐2期剂量为15 Mio IU,联合方案疗效正在ImmunoSABR 2期试验中评估。

要点

  • SBRT后1周内给予L19-IL2,15 Mio IU剂量耐受良好,无剂量限制性毒性。
  • 22.5 Mio IU(单药推荐剂量)组3例均出现剂量限制性毒性,但均恢复无后遗症。
  • 常见不良事件包括寒战、非感染性发热、乏力、水肿、红斑、瘙痒、恶心呕吐、咳嗽和呼吸困难。

核心结论

  • SBRT联合L19-IL2的推荐2期剂量为15 Mio IU。
  • 该联合方案的疗效正在多中心EU资助的2期临床试验ImmunoSABR中评估。

研究设计与样本

  • 1期临床试验,采用3+3剂量递增设计,纳入寡转移实体瘤患者。
  • 患者接受根治性SBRT照射所有可见转移灶,SBRT后1周内静脉给予L19-IL2。
  • 主要终点为安全性和耐受性,采用CTCAE 4.03评分;无进展生存和总生存为次要终点。
  • 共纳入6例患者,分布在2个L19-IL2剂量水平。

主要发现

  • 15 Mio IU剂量组耐受良好,无剂量限制性毒性。
  • 22.5 Mio IU剂量组3例患者均出现剂量限制性毒性,但恢复无后遗症。
  • 最常见不良事件为寒战、非感染性发热、乏力、水肿、红斑、瘙痒、恶心/呕吐、咳嗽和呼吸困难。
  • 血液分析异常包括肝功能检查异常、贫血、低白蛋白血症和低钾血症。
  • 记录到2例长期无进展应答者,原发肿瘤均为非小细胞肺癌。

关键数值与推荐

  • 推荐2期剂量为15 Mio IU(SBRT联合L19-IL2)。
  • 22.5 Mio IU为L19-IL2单药治疗的推荐剂量。
  • 安全性评估采用Common Terminology Criteria for Adverse Events 4.03评分系统。
  • 剂量递增采用3+3设计。

临床怎么用

  • 在SBRT后1周内联合L19-IL2时,应选用15 Mio IU剂量,而非单药推荐的22.5 Mio IU。
  • 联合治疗期间需监测寒战、发热、乏力、水肿、皮疹、消化道反应及呼吸系统症状。
  • 需监测肝功能、血红蛋白、白蛋白和血钾水平。

局限性

  • 样本量小,仅6例患者。
  • 为1期剂量递增研究,主要评估安全性和耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The immunocytokine L19-IL2 delivers interleukin-2 to the tumor by exploiting the selective L19-dependent binding of extradomain B of fibronectin on tumor blood vessels. In preclinical models, L19-IL2 has been shown to enhance the local and abscopal effects of radiation therapy. The clinical safety of L19-IL2 monotherapy has been established previously. In this study, the safety and tolerability of L19-IL2 after stereotactic body radiation therapy (SBRT) was assessed. METHODS AND MATERIALS: Patients with oligometastatic solid tumors received radical SBRT to all visible metastases. Within 1 week after SBRT, intravenous L19-IL2 using a 3 + 3 dose escalation design was administered. Safety and tolerability were analyzed as the primary endpoint using the Common Terminology Criteria for Adverse Events 4.03 scoring system, with progression-free and overall survival as secondary endpoints. RESULTS: A total of 6 patients in 2 L19-IL2 dose levels were included. The 15 million International Units (Mio IU) dose level was well tolerated with no dose-limiting toxicity. The most frequently reported adverse events were chills, noninfectious fever, fatigue, edema, erythema, pruritus, nausea/vomiting, and cough and dyspnea. Blood analysis revealed abnormalities in liver function tests, anemia, hypoalbuminemia, and hypokalemia. At the second dose level (ie, 22.5 Mio IU), which is the recommended dose for L19-IL2 monotherapy, all 3 included patients experienced dose-limiting toxicity but recovered without sequelae. We documented 2 long-term progression-free responders, both having non-small cell lung cancer as primary tumor. CONCLUSIONS: Based on the results of this phase 1 clinical trial, the recommended phase 2 dose for SBRT combined with L19-IL2 is 15 Mio IU. The therapeutic efficacy of this combination is currently being evaluated in the multicentric EU-funded phase 2 clinical trial, ImmunoSABR.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Van Limbergen EJ, Hoeben A, Lieverse RIY, et al. Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 33285270. doi:10.1016/j.ijrobp.2020.11.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。